The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1345
Bronchial Thermoplasty for Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of the Alair Bronchial Thermoplasty System (Asthmatx) for treatment of severe persistent asthma in patients ≥18 years old whose asthma is not well controlled with inhaled corticosteroids and long-acting beta2-agonists.

DRUGS FOR ASTHMA — Current treatment options for patients with severe asthma include inhaled corticosteroids, long-acting beta2-agonists (LABAs), leukotriene receptor antagonists and, for the most refractory disease, chronic oral corticosteroids. In patients with persistent allergic asthma, omalizumab (Xolair) can be tried in patients ≥12 years old.1

RATIONALE FOR THERMOPLASTY — Patients with asthma may have hypertrophy of smooth muscle that narrows the airway. Bronchial thermoplasty reduces airway smooth muscle mass and widens the airway.

THE PROCEDURE — ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bronchial Thermoplasty for Asthma
Article code: 1345a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian